Albumin dialysis molecular adsorbents recirculating system: impact of dialysate albumin concentration on detoxification efficacy.
Albumin dialysis with the molecular adsorbent recirculating system (MARS) or single pass albumin dialysis (SPAD) uses human serum albumin (HSA) as an addendum of the dialysate fluid. The purpose of this in vitro study was to evaluate the impact of the dialysate albumin concentration on removal efficacy. Heparinized human plasma (3 L/test) was spiked with creatinine (1000 mg/L), unconjugated bilirubin (100 mg/L), chenodeoxycholic acid (CDCA) (100 mg/L), and diazepam (3 mg/L). The MARS albumin circuit was primed with different amounts of HSA (150, 100, 60, and 40 g). The plasma, albumin, and dialysate flow rates were 200, 200, and 40 mL/min, respectively. Clearances were calculated based on repeated sampling during the experiments, which lasted 480 min. The effective HSA concentrations in the dialysate were 175, 115, 77, and 46 g/L, respectively. They decreased over treatment time to 147, 99, 63, and 41 g/L, respectively, due to surface adsorption. The plasma-HSA concentration remained unchanged over time in all experiments (average 39 g/L). The creatinine clearance was not impacted by dialysate HSA concentration. For the albumin-bound markers a clear correlation between HSA-concentration and clearance was demonstrated with the highest clearances for the 100 and 150 g HSA experiments. The 100 g HSA setup appeared to be the one with best cost-benefit ratio, resulting in clearances (after 1 h of treatment) of 31 mL/min creatinine, 0.3 mL/min unconjugated bilirubin, 11 mL/min CDCA, and 35 mL/min diazepam. Low albumin concentrations, such as in SPAD, result in low clearance rates for albumin-bound substances. The optimal clearances in these experiments were reached with a priming dose of 100 g HSA.
Drexler
Kerstin
K
Gambro Rostock GmbH, Rostock, Germany.
Baustian
Claas
C
Richter
Georg
G
Ludwig
Julia
J
Ramlow
Wolfgang
W
Mitzner
Steffen
S
D001663:Bilirubin / Q000378:metabolism; D002635:Chenodeoxycholic Acid / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D003956:Dialysis / Q000379:methods*; D015314:Dialysis Solutions / Q000737:chemistry*; D003975:Diazepam / Q000378:metabolism; D006801:Humans; D017093:Liver Failure; D006435:Renal Dialysis; D012709:Serum Albumin / Q000008:administration & dosage* / Q000378:metabolism; D013997:Time Factors
D015314:Dialysis Solutions; D012709:Serum Albumin; D002635:Chenodeoxycholic Acid; D003404:Creatinine; D003975:Diazepam; D001663:Bilirubin